Samuel C. Blackman Sells 11,245 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 11,245 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now owns 1,085,790 shares of the company’s stock, valued at $17,405,213.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $16.39 on Friday. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -15.91 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a one year low of $10.90 and a one year high of $18.07. The stock’s fifty day moving average price is $14.34 and its two-hundred day moving average price is $14.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period last year, the company posted ($0.54) earnings per share. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DAWN. JPMorgan Chase & Co. decreased their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $35.71.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of DAWN. Deerfield Management Company L.P. Series C lifted its position in shares of Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. First Turn Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth $13,204,000. Estuary Capital Management LP lifted its position in shares of Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in Day One Biopharmaceuticals in the second quarter valued at about $7,387,000. Finally, Point72 Asset Management L.P. bought a new position in Day One Biopharmaceuticals in the second quarter valued at about $6,480,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.